Automate Your Wheel Strategy on SRPT
With Tiblio's Option Bot, you can configure your own wheel strategy including SRPT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol SRPT
- Rev/Share 22.9388
- Book/Share 11.7368
- PB 1.0165
- Debt/Equity 1.1759
- CurrentRatio 4.0168
- ROIC -0.062
- MktCap 1172444610.0
- FreeCF/Share -7.0618
- PFCF -1.7053
- PE -4.6763
- Debt/Assets 0.3878
- DivYield 0
- ROE -0.2
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 5
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | SRPT | Barclays | Equal Weight | Underweight | -- | $10 | July 28, 2025 |
| Downgrade | SRPT | JP Morgan | Neutral | Underweight | -- | -- | July 25, 2025 |
| Initiation | SRPT | Citigroup | -- | Sell | -- | $7 | July 24, 2025 |
| Downgrade | SRPT | BofA Securities | Neutral | Underperform | -- | $10 | July 23, 2025 |
| Downgrade | SRPT | Barclays | Overweight | Equal Weight | -- | $18 | July 22, 2025 |
| Downgrade | SRPT | UBS | Buy | Neutral | -- | $12 | July 21, 2025 |
| Downgrade | SRPT | Mizuho | Outperform | Neutral | -- | $14 | July 21, 2025 |
| Downgrade | SRPT | Leerink Partners | Outperform | Market Perform | -- | $10 | July 21, 2025 |
| Downgrade | SRPT | Deutsche Bank | Buy | Hold | -- | $9 | July 21, 2025 |
| Downgrade | SRPT | Needham | Hold | Underperform | -- | -- | July 21, 2025 |
News
Levi & Korsinsky Notifies Sarepta Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – SRPT
Published: July 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT) of a class action securities lawsuit.
Read More
SRPT Shareholders Have the Right to Lead the Sarepta Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group Before the Final Deadline - SRPT
Published: July 28, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , July 28, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Sarepta Therapeutics, Inc. ("Sarepta" or "the Company") (NASDAQ: SRPT) for violations of the federal securities laws. Shareholders who purchased the Company's securities between June 22, 2023 and June 24, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before August 25, 2025.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - SRPT
Published: July 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
Read More
SRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Published: July 28, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , July 28, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Sarepta Therapeutics, Inc. ("Sarepta" or "the Company") (NASDAQ: SRPT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between June 22, 2023 and June 24, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before August 25, 2025.
Read More
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics
Published: July 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Sarepta To Contact Him Directly To Discuss Their Options
Read More
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics
Published: July 23, 2025 by: PRNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Sarepta To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 in Sarepta between June 22, 2023 and June 24, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , July 23, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Sarepta Therapeutics, Inc. ("Sarepta" …
Read More
Sarepta Therapeutics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before August 25, 2025 to Discuss Your Rights – SRPT
Published: July 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, July 22, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT) of a class action securities lawsuit.
Read More
How The Negative Developments At Sarepta Therapeutics Impact Arrowhead Pharmaceuticals
Published: July 22, 2025 by: Seeking Alpha
Sentiment: Negative
Sarepta Therapeutics' recent setbacks and restructuring have pressured Arrowhead's share price due to concerns over milestone payments and clinical program continuity. Arrowhead's financial position remains strong, even with a reduced runway caused by the lack of promised milestone payments from Sarepta. In today's article, I discuss a range of potential outcomes for the collaboration between Sarepta Therapeutics and Arrowhead Pharmaceuticals and what Arrowhead can do with its pipeline and financials.
Read More
SRPT Slides on Voluntary US Elevidys Shipment Pause Amid Scrutiny
Published: July 22, 2025 by: Zacks Investment Research
Sentiment: Negative
Sarepta stock down as it halts U.S. Elevidys shipments after FDA pressure and safety concerns tied to patient deaths due to liver failure.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - SRPT
Published: July 22, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , July 22, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
Read More
SRPT Down After Third Death in Muscular Dystrophy Gene Therapy Program
Published: July 21, 2025 by: Zacks Investment Research
Sentiment: Negative
Sarepta plummets after a third death in its muscular dystrophy program for investigational gene therapies, prompts FDA action and intensifies safety scrutiny.
Read More
Top Stock Movers Now: Verizon, Cleveland-Cliffs, Newmont, Sarepta, and More
Published: July 21, 2025 by: Investopedia
Sentiment: Positive
The S&P 500 and Nasdaq reached record highs Monday, while the Dow advanced as well, in the wake of several strong earnings reports.
Read More
BMO's Kostas Biliouris: It will be challenging for the FDA to force a market withdrawal for Sarepta
Published: July 21, 2025 by: CNBC Television
Sentiment: Positive
Kostas Biliouris, BMO Capital Markets biotech analyst, joins CNBC's 'Squawk on the Street' to discuss the latest details on Sarepta after the company declined the FDA's request to halt shipments of its gene therapy.
Read More
SRPT Shareholders Have the Right to Lead the Sarepta Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group Before the Final Deadline - SRPT
Published: July 21, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , July 21, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Sarepta Therapeutics, Inc. ("Sarepta" or "the Company") (NASDAQ: SRPT) for violations of the federal securities laws. Shareholders who purchased the Company's securities between June 22, 2023 and June 24, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before August 25, 2025.
Read More
Sarepta Stock Sinks. How Its Crisis Went From Bad to Worse.
Published: July 21, 2025 by: Barrons
Sentiment: Negative
Most investors don't see the drugmaker's executive management as credible, following the failure to disclose a patient death, a BMO survey suggests.
Read More
Sarepta Therapeutics: Why Is SRPT Stock Crashing?
Published: July 21, 2025 by: Forbes
Sentiment: Negative
Sarepta Therapeutics has plunged to new lows below $13, down over 35% in recent trading, after rejecting the FDA's request to voluntarily halt all shipments of Elevidys following a third death tied to the gene therapy. Just days after our previous analyses highlighted the company's apparent undervaluation following its restructuring, its defiant stance has now triggered fresh investor concerns, validating the regulatory risks associated with biotech stocks.
Read More
Shareholders of Sarepta Therapeutics, Inc. Should Contact The Gross Law Firm Before August 25, 2025 to Discuss Your Rights - SRPT
Published: July 21, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , July 21, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Sarepta Therapeutics, Inc. (NASDAQ: SRPT). Shareholders who purchased shares of SRPT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
Read More
SAREPTA THERAPEUTICS, INC. (NASDAQ: SRPT) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Sarepta Therapeutics, Inc. Investors of Upcoming Deadline
Published: July 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, July 21, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company. Should You Join This Class Action Lawsuit?
Read More
Sarepta stock extends decline as company declines FDA call to withdraw drug
Published: July 21, 2025 by: Market Watch
Sentiment: Negative
Sarepta Therapeutics traded lower on Monday, extending a slide as the company took the unusual step of refusing a Food and Drug Administration request to stop selling a drug tied to three deaths.
Read More
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SRPT
Published: July 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, July 20, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) between June 22, 2023 and June 24, 2025, both dates inclusive (the “Class Period”), of the important August 25, 2025 lead plaintiff deadline.
Read More
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Hims & Hers and Sarepta and Encourages Investors to Contact the Firm
Published: July 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Hims & Hers (HIMS) or Sarepta (SRPT) To Contact Him Directly To Discuss Their Options
Read More
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics
Published: July 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Sarepta To Contact Him Directly To Discuss Their Options
Read More
SRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Published: July 18, 2025 by: Business Wire
Sentiment: Neutral
LOS ANGELES--(BUSINESS WIRE)---- $SRPT--SRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm.
Read More
SRPT BREAKING NEWS: Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Announces Third Death -- Contact BFA Law by the August 25 Class Action Deadline
Published: July 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
Sarepta Therapeutics, Inc. investors that lost money are notified to contact BFA Law before the August 25, 2025 securities fraud class action deadline.
Read More
Sarepta Therapeutics, Inc. (SRPT) Strategic Restructure and ELEVIDYS Label Update Call Transcript
Published: July 18, 2025 by: Seeking Alpha
Sentiment: Neutral
Sarepta Therapeutics, Inc. (NASDAQ:SRPT ) Strategic Restructure and ELEVIDYS Label Update Conference Call July 16, 2025 4:30 PM ET Company Participants Douglas S. Ingram - President, CEO & Director Ian Estepan - Corporate Participant Louise Rodino-Klapac - Corporate Participant Conference Call Participants Anupam Rama - JPMorgan Chase & Co, Research Division Biren N.
Read More
Sarepta shares plunge 30% as future of its gene therapy appears at risk
Published: July 18, 2025 by: CNBC
Sentiment: Negative
Shares of Sarepta Therapeutics plunged more than 30% on Friday after Food and Drug Administration Commissioner Marty Makary said the agency is considering whether the company's gene therapy should stay on the market. Sarepta has reported three patient deaths related to its gene therapies.
Read More
Sarepta shares sink on 3rd patient death amid restructuring statement
Published: July 18, 2025 by: CNBC Television
Sentiment: Negative
CNBC's Angelica Peebles joins 'Squawk on the Street' with the latest news on Sarepta following a patient death.
Read More
Sarepta's Setback Deepens With Another Gene Therapy Fatality
Published: July 18, 2025 by: Benzinga
Sentiment: Negative
Sarepta Therapeutics SRPT shares plummeted on Friday following reports of a third patient death linked to its gene therapy pipeline this year, further clouding investor confidence despite the company's recent efforts to provide clarity on its restructuring and FDA label plans.
Read More
Sarepta shares sink on third gene therapy-linked death
Published: July 18, 2025 by: Proactive Investors
Sentiment: Negative
Sarepta Therapeutics Inc (NASDAQ:SRPT) shares pulled back after Thursday's gains on the announcement of a third patient death linked to the company's experimental gene therapies. The patient, who was participating in a Phase 1 trial for Sarepta's approved AAVrh74-based gene therapy targeting limb-girdle muscular dystrophy, died from acute liver failure.
Read More
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SRPT
Published: July 17, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, July 17, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) between June 22, 2023 and June 24, 2025, both dates inclusive (the “Class Period”), of the important August 25, 2025 lead plaintiff deadline.
Read More
About Sarepta Therapeutics, Inc. (SRPT)
- IPO Date 1997-06-04
- Website https://www.sarepta.com
- Industry Biotechnology
- CEO Douglas S. Ingram
- Employees 1372